Heart Rate News and Research

RSS

Heart rate is determined by the number of heartbeats per unit of time, typically expressed as beats per minute (BPM), it can vary with as the body's need for oxygen changes, such as during exercise or sleep.

Social interaction reduces physical damage to brain by heart attack: Research

A new study in mice shows how social support can help minimize some of the worst physical damages to the brain caused by a heart attack.

31 Aug 2010

Prolonged exercise shows no evidence of cardiac fatigue: Research

In a research project aimed at understanding the effect of prolonged exercise on the heart, the Karolinska Institutet and the Swedish School of Sport and Health Sciences studied a group of competitors taking part in the Adventure Racing World Championship. The results show no evidence of cardiac fatigue despite the fact that this is a continuous endurance event lasting between five and seven days.

31 Aug 2010

Running continuously over 50 or 100 miles may not be good for the heart: Study

In 2009, a study was conducted in UK by Liverpool John Moores University and the Countess of Chester Hospital to assess the effects of running in ultra-endurance races. Typically aimed at super-fit and experienced athletes, these races are held over distances exceeding 50 miles (80 kilometres). The conclusions suggest that some damage is likely to occur to the heart muscle of competitors, while 12 percent of the study group showed signs of significant cardiac damage.

31 Aug 2010

Selective lowering of heart rate reduces risk of death and hospitalization: Study

The results of a major international study presented at the European Society of Cardiology Congress in Stockholm and published simultaneously in The Lancet show, for the first time, that selectively lowering heart rate with a novel medication, ivabradine, significantly reduces risk of death and hospitalization for patients with heart failure. This also resolves a longstanding debate about whether lowering heart rate itself can actually lower the risk of heart disease progression.

30 Aug 2010

SHIFT study finds Ivabradine reduces heart failure risk

Ivabradine, a selective If inhibitor already investigated for its effects in coronary artery disease and left ventricular dysfunction, significantly lowers the risk of heart failure, according to results of the SHIFT study (Systolic Heart failure treatment with the If inhibitor ivabradine Trial).

30 Aug 2010

New campaign to create awareness on atrial fibrillation related strokes

Mission 1 Million Getting to the Heart of Stroke launches today announcing a worldwide effort to help prevent as many as 1 million atrial fibrillation (AF) related strokes through increased awareness and understanding.

30 Aug 2010

Exmovere to release vital sign monitoring infant sleepwear

Exmovere Holdings, Inc., a biomedical engineering company, today announced plans to release vital sign monitoring infant sleepwear. Exmovere is in the advanced stages of taking to market a washable, conductive fabric-based biosensor pajama called "Exmobaby." Exmobaby is the first-ever baby garment developed for remote monitoring of heart rate, emotional state and behavior.

27 Aug 2010

Expansion of rapid response systems throughout the Veterans Affairs network can reduce morbidity

Implementing a rapid response team to aid in managing "potentially unstable" patients has led to a sharp reduction in the rate of cardiac arrests at a U.S. Veterans Affairs (VA) hospital, reports a study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

27 Aug 2010

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that it has initiated a dose-defining Phase IIa trial of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure.

26 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Noninvasive monitoring of cardiac allograft vasculopathy with fast MR imaging

Cardiac allograft vasculopathy (CAV), also known as chronicle rejection, is a leading cause of graft (foreign heart) loss and death in patients who survive the first year after heart transplantation. The typical pathological change of CAV is gradually thickening of coronary wall in "foreign" heart due to continuous immunological reaction between donated heart and the host. In some cases, undetected CAV may silently cause graft failure with global myocardial ischemia without any documented infarction signs. Thus, continually monitoring development of asymptomatic CAV is important for selecting prophylactic strategies to get better prognosis. However, most current examinations of detecting CAV are invasive and with certain risks.

22 Aug 2010

NSF issues award to develop techniques for analyzing children's behavior

A team led by the Georgia Institute of Technology has received a $10 million "Expeditions in Computing" award from the National Science Foundation (NSF) to develop novel computing techniques for measuring and analyzing the behavior of children.

20 Aug 2010

USPTO rules out Oculir's claim on noninvasive glucose measuring device patent

The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.

20 Aug 2010

Neuroscience scientist unveils leverage mirror neuron theory to promote sales

The Buying Brain, Secrets for Selling to the Subconscious, a researcher in Professor Giancomo Rizzolati's neuroscience laboratory at the University of Parma in Italy was enjoying a frozen treat while a monkey sat nearby, connected to equipment that monitored his brainwave activity. Upon seeing the lab assistant enjoying the gelato, neurons in the monkey's own brain instantly fired, matching the activity the primate was observing. In effect, in his own subconscious, that monkey was going through all the motions that the lab assistant was actually performing and enjoying. Thus was launched what Dr. Pradeep explains in "The Empathic Brain" chapter as mirror neuron theory.

17 Aug 2010

Researchers pace embryonic heart with laser

Scientists at Case Western Reserve University and Vanderbilt University found that pulsed light can pace contractions in an avian embryonic heart, with no apparent damage to the tissue. The work, "Optical pacing of the embryonic heart," will be published in the advanced online issue of Nature Photonics on Aug. 15, 2010.According to the scientists, this non-invasive device may prove an effective tool in understanding how environmental factors that alter an embryo's heart rate lead to congenital defects. It may also lead to investigations of cardiac electrophysiology at the cellular, tissue and organ levels, and possibly the development of a new generation of pacemakers.

16 Aug 2010

Tracking heart rate can provide important marker of health issues: Research

An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.

13 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Simple morning walk to school could reduce stress reactivity in children: Study

A simple morning walk to school could reduce stress reactivity in children during the school day, curbing increases in heart rate and blood pressure that can lead to cardiovascular disease later in life, according to a new University at Buffalo study.

11 Aug 2010

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Along with skeletal muscles, it may be important to monitor heart function in patients with spinal muscular atrophy (SMA). These are the findings from a study conducted by Nationwide Children's Hospital and published online ahead of print in Human Molecular Genetics. This is the first study to report cardiac dysfunction in mouse models of SMA.

11 Aug 2010

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.

11 Aug 2010